New combo therapy aims to shrink liver tumors in hard-to-treat colorectal cancer

This study tests whether adding radiotherapy to a drug combination (fruquintinib and sintilimab) can help control colorectal cancer that has spread to the liver and hasn't responded to two prior treatments. About 62 adults with a specific type of colorectal cancer (MSS/pMMR) will be randomly assigned to receive the drug combo with or without radiotherapy. The goal is to see if the triple therapy improves how long the cancer stays under control and overall survival.